{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:44:17Z","timestamp":1761767057155,"version":"build-2065373602"},"reference-count":59,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Patients with atrial fibrillation (AF) are at increased risk for coronary artery disease (CAD). After percutaneous coronary intervention (PCI), the antithrombotic therapy consists of a combination of anticoagulant and antiplatelet agents to reduce the ischemic and thromboembolic risk, at the cost of increased bleeding events. In the past few years, several randomized clinical trials involving over 12,000 patients have been conducted to compare the safety of vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs) in association with a single- or double-antiplatelet agent, in the so-called dual- (DAT) or triple-antithrombotic therapy (TAT). These studies and several meta-analyses showed a consistent benefit for reducing bleeding events of DAT over TAT and of DOAC over VKA, without concerns about ischemic endpoints, except for a trend for increased stent thrombosis risk. The present paper examines current international guidelines\u2019 recommendations and reviews clinical trials, meta-analyses, and observational studies conducted on AF patients treated with DAT or TAT after PCI for acute coronary syndromes.<\/jats:p>","DOI":"10.3390\/jcm11030512","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T22:51:06Z","timestamp":1642719066000},"page":"512","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8552-1272","authenticated-orcid":false,"given":"Leonardo","family":"De Luca","sequence":"first","affiliation":[{"name":"Department of Cardiosciences, A.O. San Camillo-Forlanini, 13449 Roma, Italy"},{"name":"UniCamillus-Saint Camillus International University of Health Sciences, 00131 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Mistrulli","sequence":"additional","affiliation":[{"name":"Cardiology Department, Sapienza University of Rome, Sant\u2019Andrea Hospital, 00185 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3173-2901","authenticated-orcid":false,"given":"Francesco Antonio","family":"Veneziano","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, 00128 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Grigioni","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, 00128 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[{"name":"Cardiology Department, Sapienza University of Rome, Sant\u2019Andrea Hospital, 00185 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Musumeci","sequence":"additional","affiliation":[{"name":"Department of Cardiosciences, A.O. San Camillo-Forlanini, 13449 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Gabrielli","sequence":"additional","affiliation":[{"name":"Department of Cardiosciences, A.O. San Camillo-Forlanini, 13449 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1136\/heartjnl-2018-314267","article-title":"Mechanisms of atrial fibrillation","volume":"105","author":"Wijesurendra","year":"2019","journal-title":"Heart"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.gheart.2017.01.015","article-title":"The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation","volume":"12","author":"Murphy","year":"2017","journal-title":"Glob. Heart"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41572-019-0118-8","article-title":"Ischaemic stroke","volume":"5","author":"Campbell","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_5","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Capodanno, D., Di Maio, M., Greco, A., Bhatt, D.L., Gibson, C.M., Goette, A., Lopes, R.D., Mehran, R., Vranckx, P., and Angiolillo, D.J. (2020). Safety and Efficacy of Double Antithrombotic Therapy with Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. J. Am. Heart Assoc., 9.","DOI":"10.1161\/JAHA.120.017212"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy","volume":"139","author":"Lijfering","year":"2019","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Stroke Prevention in Atrial Fibrillation Study (1991). Final results. Circulation, 84, 527\u2013539.","DOI":"10.1161\/01.CIR.84.2.527"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.advms.2017.06.005","article-title":"Patients with atrial fibrillation and coronary artery disease-Double trouble","volume":"63","author":"Michniewicz","year":"2018","journal-title":"Adv. Med. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"ACTIVE Writing Group of the ACTIVE Investigators (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesart.tan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet, 367, 1903\u20131912.","DOI":"10.1016\/S0140-6736(06)68845-4"},{"key":"ref_11","first-page":"CD006186","article-title":"Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks","volume":"3","author":"Aguilar","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2007.11.035","article-title":"Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis","volume":"51","author":"Hurtado","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","article-title":"Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)","volume":"98","author":"Urban","year":"1998","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison","volume":"72","author":"Capodanno","year":"2018","journal-title":"J Am Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/1074248420923528","article-title":"The Combination of Oral Anticoagulant and Antiplatelet Therapies: Stay One Step Ahead","volume":"25","author":"Giubilato","year":"2020","journal-title":"J Cardiovasc. Pharmacol. Ther."},{"key":"ref_18","first-page":"100524","article-title":"Randomised trials and meta-analyses of double vs triple antitrombotic therapy fo.or atrial fibrillation-ACS\/PCI: A critical appraisal","volume":"28","author":"Galli","year":"2020","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ahj.2014.12.006","article-title":"An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)","volume":"169","author":"Gibson","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/01.STR.0000254600.92975.1f","article-title":"Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: A meta-analysis of randomized controlled trials","volume":"38","author":"Paciaroni","year":"2007","journal-title":"Stroke"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1161\/hs1001.097093","article-title":"Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial","volume":"32","author":"Saxena","year":"2001","journal-title":"Stroke"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: A joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jcin.2015.08.018","article-title":"Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study","volume":"8","author":"Jackson","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.thromres.2014.10.016","article-title":"Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome","volume":"135","author":"Braun","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/europace\/euz345","article-title":"Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: A meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention\/acute coronary syndrome patients","volume":"22","author":"Galli","year":"2020","journal-title":"Europace"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCULATIONAHA.118.034790","article-title":"Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI)","volume":"138","author":"Orme","year":"2018","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/CIRCULATIONAHA.120.048770","article-title":"Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study","volume":"142","author":"Franchi","year":"2020","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/europace\/euz259","article-title":"Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: Meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ehjcvp\/pvz030","article-title":"Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy","volume":"6","author":"Galli","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ehjcvp\/pvz021","article-title":"Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: Systematic review and meta-analysis","volume":"5","author":"Haller","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijcard.2019.12.054","article-title":"Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials","volume":"302","author":"Costa","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"474","DOI":"10.7326\/M19-3763","article-title":"Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis","volume":"172","author":"Khan","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/eurheartj\/ehy162","article-title":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials","volume":"39","author":"Golwala","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.amjcard.2017.12.014","article-title":"Meta-Analysis Comparing the Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","volume":"121","author":"Cavallari","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11239-019-01874-1","article-title":"Dual versus triple therapy for patients with atrial fibrillation and acute coronary syndrome: A meta-analysis and trial sequential analysis of randomized controlled trials","volume":"48","author":"Kheiri","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e000785","DOI":"10.1136\/openhrt-2018-000785","article-title":"Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: Meta-analysis","volume":"5","author":"Brunetti","year":"2018","journal-title":"Open Heart"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1056\/NEJMe1710753","article-title":"Triple Therapy for Atrial Fibrillation after PCI","volume":"377","author":"Piccini","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1161\/CIRCULATIONAHA.105.552984","article-title":"Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: A prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA)","volume":"112","author":"Stenestrand","year":"2005","journal-title":"Circulation"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: A nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e041044","DOI":"10.1136\/bmjopen-2020-041044","article-title":"Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: A prospective, observational, nationwide study","volume":"10","author":"Rubboli","year":"2020","journal-title":"BMJ Open"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e001677","DOI":"10.1136\/openhrt-2021-001677","article-title":"Is percutaneous coronary intervention safe during uninterrupted direct oral anticoagulant therapy in patients with atrial fibrillation and acute coronary syndromes?","volume":"8","author":"Rubboli","year":"2021","journal-title":"Open Heart"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/ehjcvp\/pvaa088","article-title":"Combinations of antithrombotic therapies prescribed after percutaneous coronary intervention in patients with acute coronary syndromes and atrial fibrillation: Data from the nationwide MATADOR-PCI registry","volume":"7","author":"Bolognese","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2021.03.029","article-title":"Post-discharge antithrombotic management and clinical outcomes of patients with new-onset or pre-existing atrial fibrillation and acute coronary syndromes undergoing coronary stenting: Follow-up data of the MATADOR-PCI study","volume":"88","author":"Rubboli","year":"2021","journal-title":"Eur. J. Intern. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/512\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:04:37Z","timestamp":1760133877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["jcm11030512"],"URL":"https:\/\/doi.org\/10.3390\/jcm11030512","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,1,20]]}}}